Core Insights - On November 6, Baicheng Pharmaceutical experienced a decline of 3.41% with a trading volume of 706 million yuan, indicating market volatility [1] - The company reported a financing buy-in of 78.38 million yuan and a financing repayment of 133 million yuan on the same day, resulting in a net financing outflow of 54.65 million yuan [1] - As of November 6, the total margin balance for Baicheng Pharmaceutical was 400 million yuan, representing 6.77% of its market capitalization, which is above the 90th percentile of the past year [1] Financial Performance - For the period from January to September 2025, Baicheng Pharmaceutical achieved a revenue of 510 million yuan, reflecting a year-on-year decrease of 29.33% [2] - The net profit attributable to the parent company was 6.12 million yuan, showing a significant decline of 95.68% compared to the previous year [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Baicheng Pharmaceutical was 10,100, a decrease of 15.05% from the previous period [2] - The average number of circulating shares per shareholder increased by 18.15% to 8,242 shares [2] Dividend Distribution - Since its A-share listing, Baicheng Pharmaceutical has distributed a total of 184 million yuan in dividends, with 119 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Baicheng Pharmaceutical saw the exit of the Rongtong Health Industry Flexible Allocation Mixed A/B fund from the list [3]
百诚医药11月6日获融资买入7837.99万元，融资余额4.00亿元